ClinicalTrials.gg
RecruitingNCT07187401Updated Jul 9, 2026

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

A Phase 1/2 interventional study of ALN-CFB and Placebo in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia, sponsored by Regeneron Pharmaceuticals. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.

Started
2026
with 1 other
Phase 1/2
Only one
of the 10
Registered
10th of 10
by date

Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2026, is the only one in phase 1/2, and was the 10th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study is researching an experimental drug called ALN-CFB. The study is focused on people with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are currently taking a complement component C5 inhibitor ("C5-inhibitor") and continue to have anemia (low red blood cell count).

The aim of the study is to see how tolerable ALN-CFB is compared to placebo. A placebo looks like the study drug but does not contain any drug.

The study is looking at several other research questions, including:

  • What side effects may happen from taking ALN-CFB
  • How much ALN-CFB is in the blood at different times
  • How much Complement Factor B (CFB) protein levels in the blood are affected by ALN-CFB
Read the detailed description

The protocol will be amended to describe Part B of the study after Part A data have been analyzed.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Persistent Anemia

Keywords

  • C5 inhibitor
  • Complement Factor B (CFB) protein
  • Red Blood Cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has been diagnosed with PNH confirmed by a history of high flow cytometry from prior testing
  2. Treated with a stable dose of C5 inhibitor (eculizumab or approved eculizumab biosimilar, ravulizumab, or crovalimab) for at least 24 weeks prior to screening visit, as described in the protocol
  3. Has ≤10.5 g/dL at screening visit 1, with evidence of anemia prior to this visit, as described in the protocol
  4. Has peripheral blood reticulocyte count of ≥100 x 10\^9/L at screening visit 1

Key Exclusion Criteria:

  1. Has history of bone marrow transplantation or receipt of an organ transplant
  2. Has history of meningococcal infection or similar recurrent infections by other encapsulated bacterial organisms
  3. Has any active, ongoing infection or a recent infection requiring ongoing systemic treatment with antibiotics, antivirals, or antifungals within 2 weeks of screening or during the screening period
  4. Has laboratory evidence of bone marrow failure, as described in the protocol
  5. Have recent, unstable medical conditions, not related to PNH or PNH-related complications, as described in the protocol

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Single-Ascending Dose Escalation

    Drug: ALN-CFB

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugALN-CFB

    Administered as defined in the protocol

  • DrugPlacebo

    Administered as defined in the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Through 365 Days

  2. Severity of TEAEs

    Time frame: Through 365 Days

Secondary outcomes

  1. Concentrations of combined ALN-CFB and major metabolites in plasma

    Time frame: Through 365 Days

  2. Concentrations of combined ALN-CFB and major metabolites in urine

    Time frame: Through 24 Hours following ALN-CFB administration

  3. Absolute change from baseline in CFB concentration

    Time frame: Baseline, Through 365 Days

  4. Percentage change from baseline in CFB concentration

    Time frame: Baseline, Through 365 Days

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Nov 2029, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Sep 23, 2025
StartActual
Feb 11, 2026
Primary completionEst.
Nov 29, 2029
CompletionEst.
Jul 15, 2031
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07187401
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Feb 11, 2026
Primary completion
Nov 29, 2029 (estimated)
Completion
Jul 15, 2031 (estimated)
Last update
Jul 9, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion